University of Groningen

Therapeutic drug monitoring in Tuberculosis treatment

van den Elsen, Simone

DOI:
[10.33612/diss.116866861](https://doi.org/10.33612/diss.116866861)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van den Elsen, S. (2020). *Therapeutic drug monitoring in Tuberculosis treatment: the use of alternative matrices and sampling strategies*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen. <https://doi.org/10.33612/diss.116866861>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Therapeutic Drug Monitoring in Tuberculosis Treatment

The use of alternative matrices and sampling strategies

Simone H.J. van den Elsen

Van den Elsen, S.H.J.

Therapeutic Drug Monitoring in Tuberculosis Treatment: The use of alternative matrices and sampling strategies

Thesis, University of Groningen, Groningen, the Netherlands

Publication of this thesis was financially supported by University of Groningen, University Medical Center Groningen, Graduate School of Medical Sciences, Stichting Beatrixoord Noord-Nederland, KNCV Tuberculosis Foundation, and Royal Dutch Pharmacists Association (KNMP).

Cover design: Simone van den Elsen

Lay-out: proefschriftenprinten.nl

Printed by: proefschriftenprinten.nl

ISBN: 978-94-034-2285-5 (printed book)

ISBN: 978-94-034-2286-2 (electronic version)

© Copyright 2020 S.H.J. van den Elsen, Groningen, the Netherlands.

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording or otherwise, without the prior written permission of the author.

rijksuniversiteit
 groningen

Therapeutic Drug Monitoring in Tuberculosis Treatment

The use of alternative matrices and sampling strategies

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 26 februari 2020 om 12.45 uur

door

Simone Hildegarde Johanna van den Elsen

geboren op 27 april 1994
te Etten-Leur

Promotores

Prof. dr. J.W.C. Alffenaar
Prof. dr. T.S. van der Werf
Prof. dr. D.J. Touw

Beoordelingscommissie

Prof. dr. Y. Stienstra
Prof. dr. K. Taxis
Prof. dr. A.D.R. Huitema

Paranimfen:

Rosemarie Cramer
Renske van der Wel

Table of contents

Chapter 1	Introduction and scope of the thesis	9
Chapter 2	Systematic Review of Salivary versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring	19
Chapter 3a	Dose Optimisation of First-line Tuberculosis Drugs using Therapeutic Drug Monitoring in Saliva: Feasible for Rifampicin, not for Isoniazid	55
Chapter 3b	Therapeutic Drug Monitoring using Saliva as Matrix: an Opportunity for Linezolid, but Challenge for Moxifloxacin	63
Chapter 3c	Lack of Penetration of Amikacin into Saliva of Tuberculosis Patients	71
Chapter 3d	Membrane Filtration is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring	77
Chapter 4a	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients	81
Chapter 4b	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients	105
Chapter 5	Prospective Evaluation of improving Fluoroquinolone Exposure using Centralized TDM in patients with Tuberculosis (PERFECT) – a study protocol of a prospective multicenter cohort study	125
Chapter 6	General discussion and future perspectives	143
Chapter 7	Summary	157
	Samenvatting	163
	Dankwoord	171
	About the author	175
	List of publications	177